Using nisin to treat oral cavity squamous cell carcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the administration of nisin, a natural food preservative, in patients with oral cavity squamous cell carcinoma (OSCC) who are undergoing surgical resection. The trial aims to determine the maximum tolerated dose of nisin and assess its feasibility and safety during treatment. Participants will be monitored for changes in tumor size, periodontal health, and oral microbiome composition, as well as overall survival and relapse-free survival rates. The study is conducted at the University of California, San Francisco, with collaboration from other institutions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Participants with a suspected clinical diagnosis of oral cavity squamous cell carcinoma (OSCC) who are planning to undergo a diagnostic biopsy. Note: Subsequent documentation from the medical record (e.g., from the diagnostic biopsy pathology report) of histological or cytological confirmation of OSCC is required prior to enrollment and treatment on study. Participants who do not have a histological/cytological confirmation of OSCC, or who are unable to provide sufficient volume of biopsy tissue for research, will not be eligible to enroll in the study.
2. OSCC mass must be \>= 2cm in size.
3. Non-metastatic OSCC (no distant metastases allowed; metastasis to the neck is eligible).
4. Participants must be planning for a complete OSCC surgical resection, with or without adjuvant radiation/chemoradiation, at UCSF, as part of their routine treatment plan. Surgical resection and adjuvant treatment will be according to the participants routine or standard of care treatment plan and will not be dictated by the study (non-interventional).
5. Age \>= 18 years
6. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 (Karnofsky ≥ 50%).
7. Participants must be dentate (retaining at least two teeth). Teeth are required for plaque sample collection for correlative studies.
8. Ability to understand and willingness to sign a written informed consent document.

Exclusion Criteria:

1. Individuals with a history of a known positive human papillomavirus deoxyribonucleic acid ((HPV DNA) test (P16-positive is permitted if HPV DNA test is negative).
2. Individuals with a history of or concurrent oropharyngeal, laryngeal, or hypopharyngeal cancers (other than OSCC). Individuals with any other prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or endpoints of this study are eligible.
3. Individuals with ongoing uncorrected oral pathology, which in the opinion of the investigator could interfere with the safety or endpoints of this study or could be exacerbated during the course of study participation, if left untreated. These conditions may be discussed with the study PI to determine eligibility.

   * Current and ongoing long-term dental treatment requiring major surgery;
   * Untreated carious lesions, severe oral infections, or known defective restorations;
   * Other suspicious uncorrected oral pathology.
4. Individuals with a known history of hypersensitivity reactions or oral allergies to nisin, any of its excipients, or any related food preservatives.
5. Individuals with complete inability to absorb nutrients via gastrointestinal tract due to major medical disorder or history of gastrointestinal surgical removal.
6. Individuals who have received extended (\>4 weeks) antibiotic therapy within 1 month of the baseline visit or who currently require continuous antibiotic prophylaxis at the time of enrollment.
7. Individuals who require treatment with a systemic anticancer therapy prior to enrollment, with the exception of prior immunotherapy which is permitted both prior to enrollment and concurrent with study participation.
8. Individuals currently receiving any other investigational agent or using an investigational device intended as anticancer therapy, with the exception of investigational immunotherapy, which is permitted both prior to enrollment and concurrent with study participation.
9. Individuals with ongoing Grade 2 events that are not clinically stable or ongoing \>= Grade 3 events (CTCAE v5.0 grading).
10. Individuals with any condition or social circumstance that, in the opinion of the investigator, would impair the participant's ability to comply with study activities, interfere with participant safety, or study endpoints.

Where it's running

• University of California, San Francisco
  San Francisco, California, United States Recruiting

Study contacts

• Principal investigator: Sue Yom, MD — University of California, San Francisco
• Study coordinator: Narimane Badawi
• Email: Narimane.Badawi@ucsf.edu
• Phone: (415) 866-7594

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Proton or Photon Radiotherapy Added to Pembrolizumab Before Surgery for Advanced or Recurrent Oral Cavity Cancer

  This phase 2 trial tests whether adding proton SFRT or SBRT to pembrolizumab before surgery helps patients with advanced or recurrent oral cavity cancer.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT07783581

• Selective neck dissection (levels I–IV) vs. modified neck dissection (levels I–V) in oral cavity cancer with a positive neck

  This trial tests whether a less extensive neck surgery can control cancer as well as the standard broader surgery in patients with one involved neck node from oral cavity cancer.

  Recruiting Kolhapur Cancer Centre - Cancer Centers of America · Kolhāpur, Maharashtra · NCT07717307

• Personalized neck radiation guided by sentinel lymph node biopsy for oral cavity cancer

  This phase II trial sees if using sentinel lymph node biopsy to guide which side(s) of the neck get radiation can safely reduce unnecessary radiation for people with oral cavity squamous cell carcinoma.

  Recruiting Phase 2 University of Michigan Rogel Cancer Center · Ann Arbor, Michigan · NCT07121595

• Personalized compartment-sparing postoperative radiation for head and neck cancer

  This trial tests whether targeted, compartment-sparing postoperative radiation can reduce side effects while keeping cancer control for people with surgically treated head and neck squamous cell carcinoma.

  Recruiting at 3 sites Phase 2 Insel Gruppe AG, University Hospital Bern · Basel and 2 other locations · NCT07058805

• Cemiplimab with or without CDX-1140 given before surgery for stage III-IV head and neck cancer

  This trial tests whether adding the immune stimulant CDX-1140 to cemiplimab before surgery helps shrink tumors in people with resectable stage III-IV head and neck squamous cell carcinoma.

  Recruiting at 12 sites Phase 2 National Cancer Institute (NCI) · Irvine, California and 11 other locations · NCT06980038

• Immune biomarker testing in cisplatin-ineligible head and neck squamous cell cancer patients treated with chemoradiation and docetaxel

  This project will test whether immune markers from tumor tissue, blood, saliva and stool can help predict outcomes and show increased tumor immune activity in people with oropharynx, hypopharynx, larynx or oral cavity squamous cell cancer who can't take cisplatin and are receiving chemoradiation with docetaxel.

  Recruiting University of Erlangen-Nürnberg Medical School · Erlangen, Bavaria · NCT06947668

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.